Logo
Home
Drug Development
Our PipelineEvaluation PipelineInaphaea BioLabsTherapeutic AreasPartnering & Useful Links
Investor News & Media
Regulatory NewsUpdatesReports, AGMs & PresentationsShare Price InformationAIM Rule 26Analyst ResearchWebinars
About Us
Board & Management TeamStrategy & VisionHow we workWorking with usCollaborative PipelinePrivacy Policy
Contact Us

ValiRx PLC - Cytolytix Commercial update

RNS

Released

Latest announcements

Announcement summary

ValiRx PLC - Cytolytix Commercial update

Very happy to announce progress on the current patents for Cytolytix. Now we have notice of allowance for the nanoparticle formulation we'll be completing formalities like filing the translations into French and German, as required by the EU patent office. We will then pay the required fee after which the patent should grant within a couple of months.

In the case of the second patent, an accelerated examination request is typically completed within 3 months followed by the same process outlined above.

For those not familiar with the patent process, it's useful to note that patent coverage begins from the priority date in the earliest patent submission, NOT the grant date so once we know claims will be granted, we know we have coverage. We are building on this strong base with new filings anticipated to cover novel aspects of the technology which we can then disclose publicly, an important part of our commercialisation strategy as we promote the program at various conferences and partnering meetings.

Ask a question


Your question will be sent privately to ValiRx plc. The company may choose to make this question public.

Investor Q&As

Start the conversation

Ask ValiRx plc a question about this announcement.

Logo

ValiRx plc

Powered by InvestorHub•Terms and conditions•Privacy policy•Cookie settings•Technical issues?
TwitterLinkedIn